Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.

Voortman J, Harada T, Chang RP, Killian JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y, Giaccone G.

Curr Pharm Des. 2013;19(5):833-40.


c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R.

Cancer Res. 2003 Oct 1;63(19):6272-81.


Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R.

Cancer Res. 2005 Feb 15;65(4):1479-88.


Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.

Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R.

Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1488-94. Epub 2007 Feb 23.


c-Met is a potentially new therapeutic target for treatment of human melanoma.

Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R.

Clin Cancer Res. 2007 Apr 1;13(7):2246-53.


Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.

Wang ZX, Lu BB, Yang JS, Wang KM, De W.

J Surg Res. 2011 Nov;171(1):127-35. doi: 10.1016/j.jss.2009.12.016. Epub 2010 Jan 14.


PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R.

Lab Invest. 2009 Mar;89(3):301-14. doi: 10.1038/labinvest.2008.168. Epub 2009 Jan 12.


MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.

Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E, Hirsch FR, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell J.

Br J Cancer. 2011 Sep 6;105(6):814-23. doi: 10.1038/bjc.2011.298. Epub 2011 Aug 16.


Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients.

Cao X, Hong X, Jia X, Zhang L, Chen G.

Med Oncol. 2014 Dec;31(12):333. doi: 10.1007/s12032-014-0333-9. Epub 2014 Nov 22.


c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.

Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I.

J Biol Chem. 2008 Feb 1;283(5):2675-83. Epub 2007 Nov 30.


Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.

Shimakage M, Kodama K, Kawahara K, Kim CJ, Ikeda Y, Yutsudo M, Inoue H.

Oncol Rep. 2009 Jun;21(6):1367-72.


Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.


Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.

Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J.

Curr Cancer Drug Targets. 2010 May;10(3):332-42.


Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.

Zimmer Y, Vaseva AV, Medová M, Streit B, Blank-Liss W, Greiner RH, Schiering N, Aebersold DM.

Cancer Lett. 2010 Mar 28;289(2):228-36. doi: 10.1016/j.canlet.2009.08.017. Epub 2009 Sep 23.


Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, Smith WI Jr, Meltzer P, Wang Y, Giaccone G.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13040-5. doi: 10.1073/pnas.1008132107. Epub 2010 Jul 6.


Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.

Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y.

Cancer Sci. 2008 Nov;99(11):2280-5. doi: 10.1111/j.1349-7006.2008.00916.x.


Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.

Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M, Travis WD.

Am J Pathol. 1996 May;148(5):1531-41.


Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.

Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R.

Br J Cancer. 2007 Aug 6;97(3):368-77. Epub 2007 Jul 31.


A novel germ line juxtamembrane Met mutation in human gastric cancer.

Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF.

Oncogene. 2000 Oct 12;19(43):4947-53.


Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL.

Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21.


Supplemental Content

Support Center